financetom
Business
financetom
/
Business
/
Toll Brothers Fiscal Q2 Net Income, Revenue Falls
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Toll Brothers Fiscal Q2 Net Income, Revenue Falls
May 26, 2025 11:12 AM

04:42 PM EDT, 05/20/2025 (MT Newswires) -- Toll Brothers ( TOL ) reported fiscal Q2 net income late Tuesday of $3.50 per diluted share, down from $4.55 a year earlier.

Analysts polled by FactSet expected $2.83.

Revenue for the quarter ended April 30 was $2.74 billion, down from $2.84 billion a year earlier.

Analysts expected $2.48 billion.

The company also reaffirmed its full year guidance.

Shares were up nearly 6% in after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Taiwan Semiconductor's Arizona Trials Match Taiwanese Plants' Productivity
Market Chatter: Taiwan Semiconductor's Arizona Trials Match Taiwanese Plants' Productivity
Sep 6, 2024
09:10 AM EDT, 09/06/2024 (MT Newswires) -- Taiwan Semiconductor Manufacturing ( TSM ) achieved productivity levels at its Arizona facility on par with its Taiwan-based plants, an indicator its big US project is on the right path, Bloomberg reported, citing a person familiar with the matter. In trial production at its first advanced US plant, the chipmaker's yield rate was...
Milestone Pharmaceuticals' Partner Ji Xing's Phase 3 Trial of Etripamil Meets Primary Endpoint
Milestone Pharmaceuticals' Partner Ji Xing's Phase 3 Trial of Etripamil Meets Primary Endpoint
Sep 6, 2024
09:08 AM EDT, 09/06/2024 (MT Newswires) -- Milestone Pharmaceuticals ( MIST ) said Friday that its licensing partner Ji Xing Pharmaceuticals reported that a phase 3 trial in China evaluating etripamil nasal spray to treat paroxysmal supraventricular tachycardia met its primary endpoint. Ji Xing said the results show a statistically significant greater proportion of patients who took etripamil converted PSVT...
Ventyx Biosciences Doses First Patient in Phase 2a Parkinson's Drug Trial
Ventyx Biosciences Doses First Patient in Phase 2a Parkinson's Drug Trial
Sep 6, 2024
09:00 AM EDT, 09/06/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) said Friday it has dosed the first patient in a phase 2a trial of its drug candidate VTX3232 for early-stage Parkinson's disease. The company said the study will assess the safety and tolerability of VTX3232, a selective NLRP3 inhibitor, over a 28-day treatment period involving about 10 patients....
Guidewire Q4 Beats Estimates, Revenue And ARR Surge
Guidewire Q4 Beats Estimates, Revenue And ARR Surge
Sep 6, 2024
Guidewire Software, Inc. ( GWRE ) shares are trading higher after the company reported fourth-quarter results on Thursday. Total revenue rose 8% Y/Y to $291.5 million, beating the consensus of $283.9 million. Subscription and support revenue increased by 29% Y/Y to $151.8 million, while license revenue decreased by 12% Y/Y to $88.9 million. Also, Services revenue fell by 2% to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved